AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06485817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Pure saline was administered as the placebo condition.~Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.~The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later.
Study NCT06485817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress State Induction
Description: ReSST is an in-house hybrid online-lab implementation of two stress induction paradigms based on the Trier Social stress test (TSST) and Iowa Social Singing Stress Test (I-SSST).~The set-up was tailored to allow repeated stress induction without diminishing effects that allowed for an online experiment panel. Stress and control state inductions were administered every-other session. The singing version of the stress test was always administered last as it was deemed more stressful during piloting.
Study NCT06485817 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress State Induction
Description: ReSST is an in-house hybrid online-lab implementation of two stress induction paradigms based on the Trier Social stress test (TSST) and Iowa Social Singing Stress Test (I-SSST).~The set-up was tailored to allow repeated stress induction without diminishing effects that allowed for an online experiment panel. Stress and control state inductions were administered every-other session. The singing version of the stress test was always administered last as it was deemed more stressful during piloting.
Study NCT06485817 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control State Induction
Description: Two different control tasks matched to the stress conditions on key parameters outlined in the protocol.
Study NCT06485817 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control State Induction
Description: Two different control tasks matched to the stress conditions on key parameters outlined in the protocol.
Study NCT06188572 — intervention group
Intervention type: OTHER
Intervention: Michigan Neuropathy Screening Instrument
Description: A two-step test consisting of symptom questionnaire and physical examination was used. The symptom questionnaire includes 15 questions about the legs and feet. Physical examination includes assessment of the appearance of the feet, Achilles reflex, thumb vibration and monofilament tests.
Study NCT06188572 — intervention group
Intervention type: OTHER
Intervention: Numeric Pain Scale
Description: In this simple method, which is frequently used to measure pain intensity in the clinic and whose validity and reliability have been demonstrated, the participant is asked to mark a number on a 10 cm scale with numbers ranging from 0 (no pain) to 10 (unbearable pain) for the pain.
Study NCT06188572 — intervention group
Intervention type: OTHER
Intervention: Mandibular Function Disorder Questionnaire
Description: This valid and reliable scale evaluating mandibular dysfunction consists of two dimensions and 17 questions.A high total score obtained from the questionnaire indicates a high level of impairment in jaw function
Study NCT06188572 — intervention group
Intervention type: OTHER
Intervention: Fonseca Anamnestic Index
Description: This scale, which is valid and reliable as a TMJ disorder assessment tool, includes 10 questions. The presence of TMD is accepted in those with a score of 25.
Study NCT06188572 — intervention group
Intervention type: OTHER
Intervention: Ferrans&Powers Quality of Life Index Diabetes Version
Description: This index consists of two parts and a total of 68 items. A high score indicates a good quality of life.
Study NCT05534347 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Addtional tube of blood needed for follow up of patients
Study NCT05534347 — intervention group
Intervention type: BIOLOGICAL
Intervention: Joint puncture
Description: Joint puncture if needed according to routine care of the patients
Study NCT05641558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 611 150mg
Description: subcutaneous injection, 150 mg (single dose treatment period) + 300mg (loading dose, week 0) + 150mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)
Study NCT05641558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 611 300mg
Description: subcutaneous injection, 300 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 1 to Week 15, 8 cycles)
Study NCT05641558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 611 600mg
Description: subcutaneous injection, 600 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)
Study NCT05641558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: During the study, placebos shall be filled timely according to the administration of the test drug to ensure the consistency of the times of administration in each group, so as to maintain the blind state.
Study NCT04677972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ebselen
Description: Glutathione peroxidase mimetic
Study NCT04677972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo containing excipients
Study NCT06359210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Responder Monthly Behavior Change Discussion Sessions
Description: Monthly behavior change discussion sessions (3 total) for 12 weeks.
Study NCT06359210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incomplete Responder Monthly Behavior Change Discussion Sessions
Description: Monthly behavior change discussion sessions (3 total) for 12 weeks.
Study NCT06359210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incomplete Responder Monthly Behavior Change Discussion Sessions + Bi-Weekly Exercise Sessions
Description: Monthly behavior change discussion sessions (3 total) for 12 weeks and attend bi-weekly (every other week) exercise classes that mirror the exercises completed in their respective community-based exercise program.
Study NCT06162767 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy by Ivor-Lewis Procedure
Description: Esophagectomy was conducted by Ivor-Lewis Procedure.
Study NCT06162767 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy by Optimized Sweet Procedure
Description: Esophagectomy was conducted by Optimized Sweet Procedure.
Study NCT04866550 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Daily record of temperature, weight, heart rate, systolic blood pressure and oxygen saturation
Study NCT04721457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Distilled Water
Description: Control group
Study NCT04721457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Povidone Iodine (PVP-I)
Description: Over-the-counter antiseptic mouth rinse
Study NCT04721457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.5% Hydrogen Peroxide (H2O2)
Description: Over-the-counter antiseptic mouth rinse
Study NCT04721457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.075% Cetylpyridinium Chloride (CPC)
Description: Over-the-counter antiseptic mouth rinse
Study NCT04721457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% Sodium Hypochlorite
Description: Over-the-counter antiseptic mouth rinse
Study NCT04721457 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No rinse group
Description: second control group
Study NCT05731713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Journey of Transformation-Native Youth Health Leadership Program curriculum
Description: Curriculum activities will include traditional storytelling and other Native American cultural arts activities (i.e., drum making, film making), as well as Traditional Ecological Knowledge (TEK) activities and field trips. Curriculum content explains leadership skills and promotes healthy decision-making around substance use and sexual health.
Study NCT06546579 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Skin sampling
Description: All individuals will self-collect skin samples and swabs and fill in a questionnaire. Subsequently, all individuals will see a professional. The professional will collect skin samples and swabs as well.
Study NCT04931927 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making Connections Intervention-Telehealth (MCI-T)
Description: Single session telehealth engagement intervention plus telehealth treatment as usual (TAU) \[MCI-T +TAU\]
Study NCT04931927 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Telehealth treatment as usual without the single session telehealth engagement intervention
Study NCT04931927 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: Telehealth treatment as usual without the single session telehealth engagement intervention
Study NCT04955912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music medicine
Description: To reduce premenstrual symptoms by applying music medicine to people with premenstrual syndrome
Study NCT06124209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TachoSil
Description: TachoSil used in Vena Cava Inferior anastomosis during liver transplantation.
Study NCT04639128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Catheter
Description: The adductor canal catheter is a medical device that consists of a tunneled catheter connected to an analgesic solution-containing reservoir that slowly infuses the anesthetic over the first 2-3 postoperative days
Study NCT04685759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Exercise Protocol
Description: Supervised aerobic, resistance, flexibility, balance, and agility exercises, which could include yoga for a total of approximately 75 minutes per in-person session.
Study NCT04685759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Exercise Protocol
Description: Supervised aerobic, resistance, flexibility, balance, and agility exercises, which could include yoga for a total of approximately 75 minutes each virtual session. A TheraBand (resistance band) will be provided to patients in this group to be used for resistance and flexibility training.
Study NCT05216614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Fluvoxamine is an SSRI used for depression and anxiety disorders. This study will investigate the efficacy of fluvoxamine for improvement of olfactory dysfunction in subjects with post-Covid-19 parosmia.
Study NCT05216614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: lactose placebo capsules identical to fluvoxamine capsules in order to preserve blind
Study NCT05455242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit formation
Description: Habit formation interventions to promote context-dependent automatic behaviors to support diabetes self-management.
Study NCT05791136 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 95% PGTV56-60Gy/28-30 fractions, 2Gy/1 fractions; 95% PTV50.4-54Gy/28-30 fractions, 1.8Gy/1 fractions; 5 days a week; 6 weeks.
Study NCT05791136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab (200 mg, intravenously infused) will be administered as the maintenance treatment every 3 weeks within 4 weeks after the completion of radiotherapy for 1 years or until progression, intolerable toxicity, or physician/patient decision
Study NCT06015373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: supress the night dose of carvedilol
Description: already described
Study NCT05955703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ppm based training
Description: The training program based on the precede proceed model was applied to hemodialysis patients for 8 sessions. Eight sessions of training were given to the experimental group within the scope of the model, a booklet was developed in line with the trainings and posters were prepared.
Study NCT05612074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Description: Inhaled nitric oxide (Medical grade, in NO/N2 tanks) will be delivered in a oxygen-air-nitrogen mixture for 30 minutes three times per day
Study NCT06087341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NKG2D-CAR memory T cell
Description: Patients will be allocated in two groups: Arm A and Arm B. Both groups will receive an intravenous infusion of NKG2D-CAR memory T cells. Additionally, patients on Arm B will receive an intratumoral dose of NKG2D-CAR memory T cells (in accessible primary tumor and metastases). The distribution of patients on one arm or other will depend on their clinical characteristics described in the inclusion/ exclusion criteria. All patients will receive lymphodepleting chemotherapy prior to the infusion of NKG2D-CAR memory T cells according to the usual clinical practice in our center. Some patients will also receive low dose radiotherapy prior to infusion.
Study NCT05019092 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound examination of lower limb veins
Description: Ultrasound examination will be performed by trained physicians using a commercially available ultrasound system and 5.0-15.0 MHz linear probe. The examinations consists of a comprehensive B-mode ultrasound protocol, from thigh to ankle, employing compression and color-Doppler at selected sites, according to the Consensus Conference of the Society of Radiologists in Ultrasound.
Study NCT06265545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib,Venetoclax,gilteritinib,Selinexor
Description: if the target gene mutations are positive, enter arm1 or arm2. other conditions, enter the chemotherapy arms (Arm3-6)
Study NCT05340881 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bright Light Exposure
Description: Research coordinator will follow-up with participant on Days 2 \& 5, and weekly thereafter to assess for the presence of potential side effects. If side effects are present with bright light initiation and they do not resolve by Day 5, the intervention will be discontinued.
Study NCT05340881 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Dim Light Exposure
Description: A placebo pair of glasses that is identical in form to the bright light glasses with the exception of light intensity will be used in a manner identical to the bright light glasses.
Study NCT05340881 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Assessment
Description: Cognitive examinations will be completed in-person and remotely via an online platform; caregivers and participants will also be asked to complete questionnaires assessing fatigue, sleep, and mood. These outcomes will be completed at baseline (prior to intervention/placebo), Week 4, Week 6 (end of intervention/placebo), and Week 8 (2-weeks post intervention/placebo).
Study NCT05340881 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Assessment
Description: Cognitive examinations will be completed in-person and remotely via an online platform; caregivers and participants will also be asked to complete questionnaires assessing fatigue, sleep, and mood. These outcomes will be completed at baseline (prior to intervention/placebo), Week 4, Week 6 (end of intervention/placebo), and Week 8 (2-weeks post intervention/placebo).
Study NCT04983550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG001
Description: Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 240 mg q2w
Study NCT04983550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride liposome injection
Description: Doxorubicin hydrochloride liposome injection 40mg/m \^2 q4w
Study NCT04983550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin hydrochloride liposome injection
Description: Doxorubicin hydrochloride liposome injection 40mg/m \^2 q4w
Study NCT06525493 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional Anesthesia
Description: The interventions are three different regional anesthesia techniques: Proximal Adductor Canal Block (ACB), iPACK (Interspace between the Popliteal Artery and the Capsule of the Posterior Knee), and Large-Volume Distal Adductor Canal Block (Large ACB distal). all three interventions were administered using ropivacaine 0.2%. However, there were differences in the volumes injected for each regional anesthesia technique. Proximal ACB: 15 mL of ropivacaine 0.2%. iPACK: 20 mL of ropivacaine 0.2%. Large ACB distal: 35 mL of ropivacaine 0.2%
Study NCT06490562 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PDCy
Description: Low dose Cy 30 mg/kg/d was administered on the 3rd and 4th day after gDLI to prevent GVHD
Study NCT06490562 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Non Cy
Description: Oral administration of low-dose CNI (CSA 25mg Q12H or FK506 0.25mg Q12H combined with azole fungal drugs) for 2 weeks to prevent GVHD at 0 days after gDLI
Study NCT05196464 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance and Commitment Therapy (ACT) Workshop
Description: ACT workshops are single-day workshops that last 5-6 hours. The workshops will 1) Acceptance and Mindfulness Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from unhelpful thoughts) and strategies to willingly face experiences that cannot be changed; and 2) Committed Action Training to help Veterans clarify what matters most to them (e.g., valued domains including family, friends, spirituality, career) and what they want to stand for in life, how they want to behave, and what strengths and qualities they want to develop. Within this context, the workshop will encourage engagement in, rather than avoidance of, actions consistent with valued directions, including engagement in healthcare. Workshop participants will be given homework related to implementing a key coping skill.
Study NCT05196464 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual (TAU)
Description: TAU will consist of a consult to a mental health provider at their rural clinic. The patient will then be scheduled for an intake and offered traditional mental health treatment options. Treatment options are likely to include outpatient individual psychotherapy, psychotherapy groups, or medication management.
Study NCT04679350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13
Description: Drug: hzVSF-v13 Dosage form: hzVSF-v13 40mg/mL in a 5mL vial Frequency: Dose at Day 1, 3, 7 Other names: a humanized monoclonal antibody (mAb)
Study NCT06646861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A combination of aerobic, resistance, balance and flexibility exercises will be included.
Study NCT06593288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Support Ventilation
Description: Conduct the Spontaneous breathing trial with pressure support
Study NCT06593288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure (CPAP)
Description: Conduct the spontaneous breathing trial with CPAP
Study NCT05741294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirbanibulin 2.5 mg ointment
Description: Participants will apply tirbanibulin 2.5 mg ointment topically for 5 consecutive days over 25 square centimeters (cm\^2) of the face or scalp.
Study NCT04679350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Normal saline solution)
Description: Dosage form: 0.9% NaCl solution Frequency: Dose at Day 1, 3, 7
Study NCT05990270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education
Description: Cervical cancer education will be provided. (The training will be in three sessions, each session will last 20-30 minutes. In the training; ppt presentation for cervical cancer, HPV virus, question and answer method will be used. In addition, female pelvic anatomy, gynecological examination, how the Pap Test is done, and cervical exam on the gynecological examination model. will be explained by showing cancer pathologies ) After the training, the final test data will be obtained by applying the questionnaire again.
Study NCT04841811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Almonertinib
Description: ctDNA dynamic monitoring guided the Almonertinib treatment group after redical surgery orradiotherapy
Study NCT04841811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: ctDNA dynamic monitoring guided the Almonertinib treatment group after redical surgery orradiotherapy
Study NCT04891159 — intervention group
Intervention type: OTHER
Intervention: Shared decision making
Description: The intervention consists of 5 components: 1) Online shared decision making training (2 hours, e-learning); 2) Individual coaching for doctors by a shared decision making expert; 3) Implementation of the shared decision making; 4) Link to institutional approaches to patient engagement; 5) Integration of the shared decision making into the multidisciplinary consultation meetings of the Cystic Fibrosis Centers Competences.
Study NCT05154539 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Remote digital assessment
Description: Remote digital assessment of test group participants
Study NCT05154539 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical assessment
Description: Conventional physical assessment of control group participants